Alpna Seth Biography and Net Worth

Director of Keros Therapeutics

Alpna Seth has served as a member of our board of directors since May 2023. Dr. Seth was most recently the President and Chief Executive Officer of Nura Bio Inc. Previously, she was the Chief Operating Officer of Vir Biotechnology, Inc. and the Senior Vice President and Global Head of the Biosimilars business for Biogen, Inc. Dr. Seth currently serves on the board of directors of Bio-Techne Corporation and Dr Reddy’s Laboratories. Dr. Seth previously served on the board of directors of Seagen Inc. (acquired by Pfizer Inc.). Dr. Seth received a Ph.D. in biochemistry and molecular biology from University of Massachusetts Medical School and conducted her post-doctoral research at Harvard University in immunology and structural biology, both as a Howard Hughes Medical Institute Fellow. She is also a graduate of the Advanced Management Program at Harvard Business School.

What is Alpna Seth's net worth?: The estimated net worth of Alpna Seth is at least $104.40 thousand as of June 4th, 2026. Dr. Seth owns 9,767 shares of Keros Therapeutics stock worth more than $104,399 as of July 17th. This net worth evaluation does not reflect any other investments that Dr. Seth may own. Learn More about Alpna Seth's net worth.
How do I contact Alpna Seth?: The corporate mailing address for Dr. Seth and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Alpna Seth's contact information.
Has Alpna Seth been buying or selling shares of Keros Therapeutics?: Alpna Seth has not been actively trading shares of Keros Therapeutics during the last quarter. Most recently, Alpna Seth sold 2,625 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.72, for a transaction totalling $28,140.00. Following the completion of the sale, the director now directly owns 9,767 shares of the company's stock, valued at $104,702.24. Learn More on Alpna Seth's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Carl Gordon (Director), Carl Gordon (Director), Julius Knowles (Director), Jennifer Lachey (Insider), Keith Regnante (CFO), and Alpna Seth (Director). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, Keros Therapeutics insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $21,890.00. During the last year, insiders at the sold shares 6 times. They sold a total of 10,185,020 shares worth more than $180,724,555.75. The most recent insider tranaction occured on June, 15th when Director Jean Jacques Bienaime bought 1,000 shares worth more than $10,190.00. Insiders at Keros Therapeutics own 12.6% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 6/15/2026.

Alpna Seth Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2026	Sell	2,625	$10.72	$28,140.00	9,767

Alpna Seth Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $10.62

$10.37

$10.76

50 Day Range

MA: $10.90

$9.91

$12.07

2 Week Range

Now: $10.62

$9.69

$22.55

Volume

56,160 shs

Average Volume

362,882 shs

Market Capitalization

$210.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97